Thilo Schroeder - 22 Jul 2022 Form 4 Insider Report for Revolution Medicines, Inc. (RVMD)

Role
Director
Signature
/s/ Darren DeStefano, Attorney-in-Fact
Issuer symbol
RVMD
Transactions as of
22 Jul 2022
Net transactions value
+$5,000,000
Form type
4
Filing time
26 Jul 2022, 17:12:23 UTC
Previous filing
29 Mar 2022
Next filing
10 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RVMD Common Stock Purchase $5,000,000 +250,000 +26% $20.00 1,221,315 22 Jul 2022 By Nextech Crossover I SCSP F1
holding RVMD Common Stock 2,668,214 22 Jul 2022 By Nextech V Oncology S.C.S., SICAV-SIF F2
holding RVMD Common Stock 300,000 22 Jul 2022 By Nextech VI Oncology SCSp F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Nextech Invest AG is the investment advisor of Nextech Crossover I SCSP ("Nextech Crossover"). The reporting person is a managing member at Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech Crossover. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
F2 Nextech Invest AG is the investment advisor of Nextech V Oncology S.C.S., SICAV-SIF ("Nextech V"). The reporting person is a managing member at Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech V. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
F3 Nextech Invest AG is the investment advisor of Nextech VI Oncology SCSp ("Nextech VI"). The reporting person is a managing member at Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech VI. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.